Please login to the form below

Not currently logged in
Email:
Password:

Pfizer resurrects its OTC bid for Viagra in the UK

Confirms MHRA review of new pharmacist-supplied status has begun

Pfizer

Nearly nine years after its last attempt to make its blockbuster erectile dysfunction treatment available without a prescription, Pfizer is having another go.

UK regulator the MHRA has began reviewing an application to allow Viagra (sildenafil) to be made available without a prescription if supplied by a pharmacist - a move that would grant it ‘P’, though not OTC (over-the-counter), status.

If approved, Pfizer’s plans would see it continue to market the medicine as a prescription-only treatment under the Viagra brand and then it would provide pharmacists with training on dispensing sildenafil at a 50mg dose.

Pfizer’s UK medical director Dr Berkeley Phillips said: “The availability of pharmacist-supplied, non-prescription sildenafil could offer men a new and additional way to access a legitimate, long established, and well-studied treatment for erectile dysfunction.

“This could have further benefits as the condition may be an early warning sign of a more serious underlying condition, such as heart disease4, which may otherwise go undetected.”

Pfizer has previously tried for European approval to make Viagra available without a prescription, but those plans were scuppered in 2008 after regulatory advisors voiced concerns about misuse of the drug.

Article by
Dominic Tyer

28th March 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics